SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
Last trade$19.45
Day change+$11.98 (+160.31%)
Day range$7.62 – $33.36
Volume104,836,896
Market cap$1.52B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$1.52B
Price / earnings
—
Price / book
11.55×
Price / sales
—
EV / sales
—
EV / EBITDA
-35.19×
Profitability
Earnings per share
-$0.18
Return on assets
-25.35%
Return on equity
-27.13%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
14.92×
Quick ratio
14.92×
Cash ratio
14.51×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$27.3M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for SLS, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$4.28M
$4.36M
$4.12M
$3.53M
$2.87M
$3M
$2.86M
$2.48M
Research and development
$7.03M
$6.27M
$5.13M
$4.73M
$4.22M
$3.87M
$3.21M
$4.44M
Total operating expenses
$11.31M
$10.63M
$9.25M
$8.26M
$7.08M
$6.87M
$6.06M
$6.92M
Operating income
-$11.31M
-$10.63M
-$9.25M
-$8.26M
-$7.08M
-$6.87M
-$6.06M
-$6.92M
Interest expense
$1.22M
$0
$0
$0
$292K
$0
$0
$0
Income before taxes
-$10.09M
-$9.61M
-$8.41M
-$7.66M
-$6.79M
-$6.6M
-$5.81M
-$6.74M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$10.09M
-$9.61M
-$8.41M
-$7.66M
-$6.79M
-$6.6M
-$5.81M
-$6.74M
Net income attributable to common shareholders
-$10.09M
-$9.61M
-$8.41M
-$7.66M
-$6.79M
-$6.6M
-$5.81M
-$6.74M
EBITDA
-$11.31M
-$10.63M
-$9.25M
-$8.26M
-$7.08M
-$6.87M
-$6.06M
-$6.92M
Basic earnings per share
-$0.05
-$0.05
-$0.05
-$0.05
-$0.06
-$0.07
-$0.07
-$0.09
Diluted earnings per share
-$0.05
-$0.05
-$0.05
-$0.05
-$0.06
-$0.07
-$0.07
-$0.09
Recent news
Company coverage with links to the original publishers.
SELLAS Life Sciences announced positive topline results from its Phase 3 REGAL trial of galinpepimut-S (GPS), an immunotherapeutic cancer vaccine for acute myeloid leukemia. GPS demonstrated a statistically significant 41% reduction in risk of death with median overall survival of 24.0 months versus 14.7 months for best available treatment (hazard ratio 0.59, p=0.035). The company plans to meet with the FDA and submit a Biologics License Application in the first half of 2027.
Pomerantz LLP announced investigations into securities fraud claims against SELLAS Life Sciences, JinkoSolar, and Stitch Fix. The investigation into SELLAS focuses on delayed release of phase 3 clinical trial results for Galinpepimut-S, which triggered an 13.15% stock price decline on August 28, 2026.
Pomerantz LLP is investigating potential securities fraud claims against SELLAS Life Sciences Group, Inc. following reports that the company failed to timely release phase 3 clinical trial results for Galinpepimut-S after reaching a pre-specified trigger event (80th patient death). The stock declined 13.15% to $13.21 per share on August 28, 2026, following the news.
Multiple biotech companies are advancing innovative immunotherapy and targeted treatments for blood cancers, with significant clinical trial progress and FDA approvals in acute myeloid leukemia (AML) and related hematologic conditions.
Several biotech companies are advancing cancer research with promising clinical milestones, focusing on innovative immunotherapies and targeted treatments amid rising cancer incidence and potential research funding challenges.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
Ex-dividend
Amount / share
Pay date
Type
Mar 24, 2011
$240.30
Apr 5, 2011
unknown
Dec 9, 2010
$421.30
Dec 20, 2010
unknown
Sep 9, 2010
$150.00
Sep 22, 2010
unknown
Jun 10, 2010
$85.00
Jun 21, 2010
unknown
Mar 18, 2010
$85.00
Mar 29, 2010
unknown
Stock splits
Historical share-structure events and their execution dates.